UY32054A - STABLE SOLID FORMULATION OF A GC-C RECEIVER AGONIST POLYPEPTIDE FOR ORAL ADMINISTRATION. - Google Patents

STABLE SOLID FORMULATION OF A GC-C RECEIVER AGONIST POLYPEPTIDE FOR ORAL ADMINISTRATION.

Info

Publication number
UY32054A
UY32054A UY0001032054A UY32054A UY32054A UY 32054 A UY32054 A UY 32054A UY 0001032054 A UY0001032054 A UY 0001032054A UY 32054 A UY32054 A UY 32054A UY 32054 A UY32054 A UY 32054A
Authority
UY
Uruguay
Prior art keywords
oral administration
linaclotide
formulations
stable solid
solid formulation
Prior art date
Application number
UY0001032054A
Other languages
Spanish (es)
Inventor
Fretzen Angelika
Witowski Steven
Grossi Alfredo
Zhao Hong
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of UY32054A publication Critical patent/UY32054A/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02W—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO WASTEWATER TREATMENT OR WASTE MANAGEMENT
    • Y02W90/00—Enabling technologies or technologies with a potential or indirect contribution to greenhouse gas [GHG] emissions mitigation
    • Y02W90/10—Bio-packaging, e.g. packing containers made from renewable resources or bio-plastics

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen en la presente formulaciones sólidas estables de linaclotida adecuadas para la administración oral así como métodos para preparar dichas formulaciones. Las formulaciones descritas en la presente contienen un polipéptido que consiste de la secuencia de aminoácidos Cys Glu Tyr Cys Asn Pro Ala Cys Thr Gly Cys Tyr ("linaclotida") o una de sus sales farmacéuticamente aceptables. Las formulaciones de linaclotida descritas en la presente son estables y tienen suficiente vida de depósito para fabricar, almacenar y distribuir el fármaco.Stable solid formulations of linaclotide suitable for oral administration as well as methods for preparing such formulations are described herein. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Glu Tyr Cys Asn Pro Ala Cys Thr Gly Cys Tyr ("linaclotide") or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have sufficient shelf life to manufacture, store and distribute the drug.

UY0001032054A 2008-08-15 2009-08-17 STABLE SOLID FORMULATION OF A GC-C RECEIVER AGONIST POLYPEPTIDE FOR ORAL ADMINISTRATION. UY32054A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8942208P 2008-08-15 2008-08-15
US27333209P 2009-08-03 2009-08-03

Publications (1)

Publication Number Publication Date
UY32054A true UY32054A (en) 2010-03-26

Family

ID=43302767

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032054A UY32054A (en) 2008-08-15 2009-08-17 STABLE SOLID FORMULATION OF A GC-C RECEIVER AGONIST POLYPEPTIDE FOR ORAL ADMINISTRATION.

Country Status (3)

Country Link
AR (1) AR073075A1 (en)
TW (1) TWI531374B (en)
UY (1) UY32054A (en)

Also Published As

Publication number Publication date
TW201023874A (en) 2010-07-01
AR073075A1 (en) 2010-10-13
TWI531374B (en) 2016-05-01

Similar Documents

Publication Publication Date Title
CO6351746A2 (en) STABLE SOLID FORMULATION OF A GC-C RECEIVER AGONIST POLYPEPTIDE FOR ORAL ADMINISTRATION
CY1123334T1 (en) FINASTERIDE FORMULATIONS FOR DRUG RELEASE IN THE HAIR AND SCALP
CY1119243T1 (en) VEGF COMPONENT PHARMACEUTICAL FORMS
TW200637615A (en) Therapeutic peptide formulations with improved stability
MX2007005521A (en) Stable formulations of insulinoptropic peptides.
WO2010027405A3 (en) Formulations of gc-c receptor agonist polypeptides
CY1122771T1 (en) Sustained-release pharmaceutical forms for the administration of proteins to the eye and methods of their preparation
PH12014501642A1 (en) Peptide vaccines for cancers expressing tumor-associated antigens
WO2009158704A3 (en) Therapeutic agents comprising elastin-like peptides
RS53559B1 (en) Long-acting formulations of insulins
NZ621868A (en) Growth hormone polypeptides and methods of making and using same
MX2009002547A (en) Fusion peptide therapeutic compositions.
CO6361952A2 (en) FORMULATION OF ANTIBODY
WO2009086400A3 (en) Recombinant vwf formulations
MY160652A (en) Pharmaceutical composition for oral administration
BR112015011179A2 (en) stable aqueous compositions comprising human insulin or an analog or derivative thereof
NZ593190A (en) Factor viii formulations
WO2009025196A1 (en) Foxm1 peptide and medicinal agent comprising the same
MA32622B1 (en) QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION COMPRISING THE SAME
AR083528A1 (en) GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE ANALOGS
AR088727A1 (en) CYCLE PEPTIDES WITH ANTINEOPLASIC AND ANTIANGIOGEN ACTIVITY
AR118601A2 (en) STABLE SOLID FORMULATIONS OF A GC-C RECEPTOR, POLYPEPTIDIC AGONIST SUITABLE FOR ORAL ADMINISTRATION
ES2377635T3 (en) Analogous peptide analogous peptide derivative compounds Crotalus durissus terrificus, its uses, compositions, preparation and purification procedures
UY32054A (en) STABLE SOLID FORMULATION OF A GC-C RECEIVER AGONIST POLYPEPTIDE FOR ORAL ADMINISTRATION.
ECSP11010897A (en) STABLE SOLID FORMULATION OF A RECEPTOR AGONIST POLYPEPTIDE

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20210303